Is Egrifta (Tesamorelin) Legal in New York?

What Is Egrifta (Tesamorelin) and Why Does Legal Status Matter?

Tesamorelin is a synthetic analogue of growth-hormone-releasing hormone (GHRH). It binds pituitary GHRH receptors and stimulates endogenous growth hormone secretion, which in turn reduces visceral adipose tissue. The FDA granted approval under NDA 022505 in November 2010, making Egrifta the first GHRH analogue approved in the United States for any indication. [1]

Legal status matters for two practical reasons. First, obtaining a peptide without a prescription or from an unregulated source exposes the patient to adulteration risk and the provider to licensure sanctions. Second, New York has a relatively strict pharmacy practice act that limits dispensing of compounded drugs to situations where a commercial equivalent is unavailable or clinically unsuitable, so patients need to understand which pathway applies to their situation.

FDA Approval History

The original Egrifta formulation (1 mg/vial) was approved in 2010. [1] Theratechnologies reformulated the product as Egrifta SV (2 mg/vial), which received FDA approval in 2019 under the same NDA. [2] The updated formulation eliminates the need for refrigeration after reconstitution for up to three days, improving real-world usability. Both formulations carry identical labeling for indication and dosing.

Mechanism of Action in Brief

Tesamorelin stimulates the pituitary gland to release growth hormone in a pulsatile, physiologic pattern. Growth hormone then elevates insulin-like growth factor-1 (IGF-1), which reduces lipolysis inhibition in visceral adipocytes. In the key LIPO-010 and LIPO-011 trials (combined N=816), tesamorelin 2 mg/day reduced visceral adipose tissue area by a mean of 18% versus placebo at 26 weeks (P<0.0001). [3]

Federal Legal Framework: FDA, DEA, and the Prescription Requirement

Egrifta is a legend drug, meaning federal law under 21 U.S.C. § 353(b) requires a prescription from a licensed practitioner. [4] It is not a controlled substance under the Controlled Substances Act, so there is no DEA Schedule attached to it and no prescription quantity limits imposed by federal drug-scheduling law. [5]

FDA Approved Indication vs. Off-Label Use

The FDA-approved indication is specifically reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. [1] Prescribing tesamorelin for other purposes, such as age-related growth hormone decline or body composition optimization in non-HIV patients, is off-label. Off-label prescribing is legal in the United States. The FDA does not regulate the practice of medicine, and physicians may prescribe approved drugs for unapproved uses supported by clinical judgment and evidence. [4]

A 2012 paper in the Journal of Clinical Endocrinology and Metabolism noted that tesamorelin reduced visceral fat in non-HIV adults as well, though the sample size was small (N=61). [6] That evidence base is thinner than the HIV-lipodystrophy data, but it informs off-label use discussions between patients and prescribers.

Is Tesamorelin on the FDA Bulk Drug Substances List?

This is the most common source of confusion. Compounding pharmacies may use bulk active pharmaceutical ingredients (APIs) only if those substances appear on specific FDA lists or meet the conditions of 503A or 503B of the Federal Food, Drug, and Cosmetic Act. [7] Tesamorelin is not currently on the FDA's 503A Bulk Drug Substances Nominated List nor on the Category 1 list of substances that may be used in compounding. [8]

That means a 503A compounding pharmacy cannot legally prepare tesamorelin as a non-patient-specific bulk compound unless a clinical need exists that the commercial product cannot address (e.g., a different concentration for a patient with a documented allergy to an excipient). The commercial brand, Egrifta SV, is the standard legal path for most patients. Patients and prescribers should verify the current list status directly with the FDA before assuming compounded tesamorelin is available through a particular pharmacy. [8]

New York State Legal Framework

New York does not add a separate state-level scheduling or restriction for tesamorelin beyond what federal law requires. The New York State Department of Health and the New York State Board of Pharmacy govern prescribing and dispensing within the state, and neither has published a specific tesamorelin restriction. [9]

New York Prescribing Authority

Any of the following New York-licensed practitioners may prescribe Egrifta, provided they conduct a good-faith patient evaluation and document medical necessity:

• Medical Doctors (MD) licensed under New York Education Law Article 131
• Doctors of Osteopathic Medicine (DO) under the same article
• Nurse Practitioners (NP) with a Collaborative Practice Agreement or full practice authority depending on their licensure category
• Physician Assistants (PA) under a practice agreement with a supervising physician

New York Education Law §6810 governs the dispensing of prescription drugs, and §6530 defines professional misconduct. Prescribing without a valid patient-provider relationship constitutes professional misconduct regardless of the drug involved. [9]

New York Compounding Pharmacy Rules

The New York State Board of Pharmacy follows federal 503A and 503B frameworks for compounded preparations. [10] A 503A pharmacy in New York may compound tesamorelin only for an individual patient with a valid prescription and a documented clinical reason the commercial product is unsuitable. A 503B outsourcing facility may produce tesamorelin in larger batches without a patient-specific prescription, but the substance must meet FDA bulk-list requirements, which, as noted above, tesamorelin currently does not satisfy without specific conditions being met. [7]

Patients who encounter online pharmacies or "peptide suppliers" selling tesamorelin without a prescription should be aware that this violates both federal law (21 U.S.C. § 353(b)) and New York Education Law §6810. [4] [9]

Telehealth Prescribing in New York

New York State legalized ongoing telehealth prescribing for most drugs during the COVID-19 public health emergency, and subsequent legislation made most of those allowances permanent. [11] A prescriber located in New York or a prescriber licensed in New York may conduct a telemedicine evaluation and issue a tesamorelin prescription electronically. The prescriber must hold a valid New York license and conduct a synchronous (real-time audio-visual) evaluation that meets the standard of care, consistent with New York Public Health Law §2999-cc. [11]

Clinical Evidence Supporting Tesamorelin Prescribing

Understanding the evidence base helps patients make informed decisions and helps prescribers justify medical necessity documentation.

Phase 3 Key Trials (LIPO-010 and LIPO-011)

The FDA approval was supported by two Phase 3, randomized, double-blind, placebo-controlled trials. LIPO-010 enrolled 412 HIV-positive adults with lipodystrophy and randomized them 2:1 to tesamorelin 2 mg/day or placebo for 26 weeks. Tesamorelin reduced visceral adipose tissue area by 18.4% from baseline versus a 5.1% increase in the placebo group (P<0.0001). [3]

LIPO-011 extended the observation to 52 weeks in a subset and confirmed durability of effect. Patients who discontinued tesamorelin after 26 weeks regained visceral fat at rates similar to placebo, which has implications for long-term therapy planning. [3]

Metabolic and Cardiovascular Effects

A concern with any agent that raises IGF-1 is glucose dysregulation. In the LIPO trials, tesamorelin produced a small but statistically significant increase in fasting glucose compared to placebo. The prescribing label carries a warning regarding diabetes and impaired glucose tolerance, and monitoring of HbA1c every 3 to 6 months is standard practice. [1]

A 2014 analysis published in Clinical Infectious Diseases (N=391) found no significant difference in major adverse cardiovascular events between tesamorelin and placebo at 52 weeks, though the study was not powered for cardiovascular outcomes. [12]

IGF-1 Monitoring

The FDA label recommends measuring IGF-1 levels approximately 4 weeks after initiation and every 6 months during therapy. If IGF-1 exceeds the upper limit of normal for age and sex, the dose should be reduced or held. [1] This monitoring requirement is one reason tesamorelin requires ongoing prescriber oversight rather than over-the-counter availability.

How to Get Egrifta (Tesamorelin) in New York: Step-by-Step

Getting Egrifta legally in New York involves four steps. Each step has a specific requirement that, if skipped, creates either a legal or a clinical risk.

Step 1: Confirm a Qualifying Indication or Off-Label Rationale

For the approved indication, the prescriber documents HIV-positive status plus evidence of lipodystrophy (typically CT-measured visceral adipose tissue area above 130 cm² or clinical examination findings consistent with trunk fat accumulation). [3]

For off-label use, the prescriber documents the clinical rationale, including any relevant laboratory findings such as low IGF-1, low growth hormone stimulation test results, or other clinical criteria, and obtains informed consent noting the off-label nature of the therapy.

Step 2: Establish Care with a Licensed New York Prescriber

Patients may establish care through:

• An in-person endocrinologist, infectious disease specialist, or primary care physician in New York
• A telehealth platform staffed by NY-licensed prescribers who offer hormone or peptide therapy evaluations

The prescriber must review baseline labs. Minimum workup before prescribing includes fasting glucose, HbA1c, IGF-1, and basic metabolic panel. [1]

Step 3: Obtain the Prescription and Fill It

Once the prescriber issues the prescription, the patient may fill it at any licensed New York pharmacy that stocks Egrifta SV, or at a specialty pharmacy that handles injectables. Egrifta SV is not typically stocked at retail pharmacies; specialty distribution through Theratechnologies' patient access program or through specialty pharmacy networks is the norm.

For patients with HIV and a confirmed lipodystrophy diagnosis, insurance coverage may apply. The manufacturer offers a patient assistance program (Th!nkplus) that may reduce out-of-pocket costs. [13]

Step 4: Monitor and Follow Up

After 4 weeks, recheck IGF-1 and fasting glucose. After 3 months, reassess visceral fat clinically or with imaging. If no meaningful reduction occurs by 26 weeks, the FDA label recommends re-evaluating the therapy. [1] Ongoing prescribing requires documented evidence of continued benefit.

Risks of Obtaining Tesamorelin Outside Legal Channels

Research-grade or "peptide supplier" tesamorelin is sold online without a prescription. These products are not FDA-regulated, not pharmaceutical-grade, and carry serious risks including microbial contamination, incorrect concentration, and the presence of unknown impurities. A 2020 FDA warning letter to a peptide supplier identified sterility failures and mislabeling in injectable peptide products. [14]

Beyond product quality, purchasing prescription drugs without a valid prescription violates 21 U.S.C. § 353(b) at the federal level and New York Education Law §6810 at the state level. [4] [9] The penalties include civil and criminal liability. No telehealth company or prescriber operating legally can authorize the use of a non-pharmaceutical-grade injectable.

Insurance Coverage and Cost in New York

Egrifta SV carries a list price of approximately $6,000 to $8,000 per month without coverage. For patients with the approved indication (HIV-associated lipodystrophy), coverage through Medicaid, Medicare Part D, and most commercial plans is possible but requires prior authorization demonstrating HIV-positive status and documented lipodystrophy. [13]

New York Medicaid covers Egrifta SV for the approved indication when medical necessity criteria are met, consistent with New York State Medicaid drug utilization review policies. [9] Prior authorization forms typically require CD4 count, viral load, HIV treatment history, and evidence of fat maldistribution.

For off-label use, insurance coverage is unlikely without a strong letter of medical necessity and supporting literature. Patients pursuing off-label use typically pay out of pocket or through health-sharing arrangements.

Special Populations and Contraindications Relevant to New York Prescribers

The FDA label lists several absolute contraindications that New York prescribers must screen for before issuing a prescription. [1]

Active malignancy is the primary contraindication. Because tesamorelin raises IGF-1, which is a mitogen, prescribing in patients with active or suspected malignancy is contraindicated. Patients with a history of cancer require a careful risk-benefit discussion, and prescribers should document oncology consultation or review of current cancer surveillance. [1]

Pregnancy is a contraindication. Tesamorelin is rated FDA Pregnancy Category X based on animal reproduction studies showing fetal harm. [1] New York prescribers must confirm that female patients of reproductive age are not pregnant before initiating therapy and must discuss contraception if appropriate.

Pituitary disease or hypopituitarism may blunt or alter the response to tesamorelin and requires endocrinology evaluation before initiation. [1]

Patients with pre-existing type 2 diabetes should have optimized glycemic control before starting tesamorelin. The label notes that new-onset diabetes occurred in 3.9% of tesamorelin patients versus 1.2% of placebo patients in the LIPO trials. [3] HbA1c above 8% at baseline is generally considered a relative contraindication in clinical practice.

What New York Patients Should Ask Their Prescriber

Patients seeking tesamorelin in New York benefit from coming to their appointment prepared. Relevant questions include:

• Does my clinical picture meet the approved indication, or is this off-label? What documentation supports prescribing?
• Which specialty pharmacy will fill the prescription, and what is the prior-authorization process for my insurance?
• How will we monitor IGF-1 and fasting glucose, and at what interval?
• What is the expected timeline for a measurable reduction in visceral fat?
• Under what circumstances would you discontinue the therapy?

The Endocrine Society's 2011 clinical practice guideline on growth hormone deficiency in adults states: "We suggest against the use of GH therapy in patients with active malignancy, diabetic retinopathy, or critical illness." [15] While that guideline addresses GH rather than GHRH analogues specifically, New York prescribers apply similar caution when evaluating tesamorelin candidates outside the HIV-lipodystrophy indication.